Diaceutics (LON:DXRX) Announces Earnings Results

Diaceutics (LON:DXRX) posted its quarterly earnings data on Tuesday. The company reported GBX (3.27) earnings per share (EPS) for the quarter, Digital Look Earnings reports. Diaceutics had a return on equity of 0.25% and a net margin of 0.25%.

Diaceutics Stock Performance

Shares of DXRX opened at GBX 194.35 on Thursday. The stock has a 50 day moving average of GBX 146.97 and a 200 day moving average of GBX 151.24. The company has a market capitalization of £164.93 million, a price-to-earnings ratio of 1,766.82 and a beta of 0.88. Diaceutics has a 12 month low of GBX 125 and a 12 month high of GBX 197. The company has a current ratio of 3.43, a quick ratio of 9.92 and a debt-to-equity ratio of 2.85.

Wall Street Analyst Weigh In

Separately, Canaccord Genuity Group reissued a “buy” rating and set a GBX 215 price target on shares of Diaceutics in a research report on Tuesday. Two research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of GBX 215.

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world’s leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX – The Diagnostics Network®.